Global News

BioCrossroads Indiana Seed Fund II makes first investments in start-ups

Friday, January 11, 2013 02:42 PM

BioCrossroads Indiana Seed Fund II, an $8.25 million early-stage fund focused on identifying, creating and developing the next generation of leading Indiana-based life sciences companies, has made its first two investments: Esanex, a company developing an oncology drug, and Algaeon, which has developed an algae cultivation technology for use in the nutraceutical and micronutrient markets. 

More... »

Altravax awarded $1.2M to advance dengue vaccine and hep B therapeutic

Friday, January 11, 2013 11:13 AM

Altravax, a privately held biopharmaceutical company based in Fargo, N.D., has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH's National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax's two lead commercial programs.

More... »

Hikma to acquire the EPCI in Egypt

Friday, January 11, 2013 10:44 AM

Hikma Pharmaceuticals, a multinational pharmaceutical group, has agreed to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI) from a consortium of shareholders for an aggregate cash consideration of approximately $22.2 million.

More... »

AtheroNova names Shaw as new clinical affairs officer

Thursday, January 10, 2013 08:00 AM

AtheroNova, a biotech company focused on compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has appointed Joan E. Shaw, MT (ASCP), SCC as senior director of clinical operations.

More... »

CoDa boasts positive results in phase IIb study of Nexagon in chronic venous leg ulcers

Thursday, January 10, 2013 08:00 AM

CoDa Therapeutics, a clinical stage biotechnology company, released positive results from a phase IIb clinical trial of Nexagon in patients with chronic venous leg ulcers, which supports advancing Nexagon into phase III registration trials.

More... »

OPKO Health to acquire Cytochroma

Wednesday, January 9, 2013 03:02 PM

OPKO Health, a multinational pharmaceutical & diagnostics company, has agreed to acquire Cytochroma, a clinical-stage specialty pharmaceutical company.

More... »

Sorrento Therapeutics acquires rights to produce rIVIG

Wednesday, January 9, 2013 02:33 PM

Sorrento Therapeutics, a development-stage biopharmaceutical company, has acquired worldwide rights that will allow for the application of its antibody library technology for the production of recombinant Intravenous immunoglobulins (rIVIG).

More... »

Priaxon, GSK collaborate on PPIs

Wednesday, January 9, 2013 11:39 AM

Priaxon, an emerging pharmaceutical company based in Germany, has formed a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions.

More... »

Daiichi Sankyo, Amplimmune to develop AMP-110 therapy for autoimmune disease

Wednesday, January 9, 2013 10:42 AM

Japan-based Daiichi Sankyo and Amplimmune, a Gaithersburg, Md.-based developer of novel co-stimulatory/co-inhibitory molecules that rebalance the immune system,  have entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein). 

More... »

Shire to acquire Lotus Tissue Repair

Wednesday, January 9, 2013 09:45 AM

Shire, a global specialty biopharmaceutical company, has signed an agreement to acquire Lotus Tissue Repair, a Cambridge, Mass.-based biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB).

More... »